Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent individuals by Passamonti, Luca et al.
ORIGINAL INVESTIGATION
Atomoxetine effects on attentional bias to drug-related cues
in cocaine dependent individuals
Luca Passamonti1,2 & M. Luijten3 & H. Ziauddeen4 & I. T. S. Coyle-Gilchrist1 &
T. Rittman1 & S. A. E. Brain1 & R. Regenthal5 & I. H. A. Franken6 & B. J. Sahakian7 &
E. T. Bullmore7,8 & T. W. Robbins7 & K. D. Ersche7
Received: 12 November 2016 /Accepted: 11 May 2017 /Published online: 27 May 2017
# The Author(s) 2017. This article is an open access publication
Abstract
Rationale Biased attention towards drug-related cues and
reduced inhibitory control over the regulation of drug-
intake characterize drug addiction. The noradrenaline
system has been critically implicated in both attentional
and response inhibitory processes and is directly affect-
ed by drugs such as cocaine.
Objectives We examined the potentially beneficial effects
of the noradrenaline reuptake inhibitor atomoxetine in
improving cognitive control during two tasks that used
cocaine- and non-cocaine-related stimuli.
Methods A double-blind, placebo-controlled, and cross-over
psycho-pharmacological design was employed. A single oral
dose of atomoxetine (40 mg) was administered to 28 cocaine-
dependent individuals (CDIs) and 28 healthy controls. All
participants performed a pictorial attentional bias task involv-
ing both cocaine- and non-cocaine-related pictures as well as a
verbal go/no-go task composed of cocaine- and food-related
words.
Results As expected, CDIs showed attentional bias to
cocaine-related cues whilst controls did not. More important-
ly, however, atomoxetine, relative to placebo, significantly
attenuated attentional bias in CDIs (F26 = 6.73, P = 0.01).
During the go/no-go task, there was a treatment × trial × group
interaction, although this finding only showed a trend towards
statistical significance (F26 = 3.38, P = 0.07).
Conclusions Our findings suggest that atomoxetine reduces
attentional bias to drug-related cues in CDIs. This may result
from atomoxetine’s modulation of the balance between tonic/
phasic activity in the locus coeruleus and the possibly parallel
enhancement of noradrenergic neurotransmission within the
prefrontal cortex. Studying how cognitive enhancers such as
atomoxetine influence key neurocognitive indices in cocaine
addiction may help to develop reliable biomarkers for patient
stratification in future clinical trials.
Keywords Attentional bias . Response inhibition . Cocaine
addiction . Noradrenaline . Atomoxetine
Introduction
Addiction to cocaine remains a significant public health prob-
lem, and with current treatment provision confined to psycho-
social interventions, there is a pressing need to improve the
breadth and nature of the therapeutic approaches to cocaine
dependence (Goldstein et al. 2009; Lapeyre-Mestre and Dupui
2015; Wiessing 2005). There is also a consensus that enhanc-
ing our knowledge of the cognitive factors that underlie
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cocaine taking might help in developing new interventions to
ameliorate the chances of recovery in cocaine-dependent in-
dividuals (CDIs).
Cocaine-related cues capture the attention of CDIs and may
influence their cocaine-taking behaviour (Marissen et al. 2006;
Waters et al. 2012). Whilst performing cognitive tasks, CDIs,
relative to controls, display biased attention towards distracting
cocaine-related stimuli (Dunning et al. 2011; Ersche et al. 2010;
Field et al. 2014;Goldstein et al. 2007;Hester et al. 2006; Leeman
et al. 2014; Smith et al. 2013), although this ‘attentional bias’
should not necessarily be considered to be abnormal per se as it
can also be observed in healthy people even in the absence of any
experimental manipulation (Pintzinger et al. 2016) or can be
trained towards stimuli linked to salient and evolutionary impor-
tant outcomes (Schmidt et al. 2016).
The inhibitory control of maladaptive impulsive responses is
another keymechanism that influences cocaine-taking behaviour;
in other words, impulsivity represents a critical predictor of vul-
nerability for cocaine taking and relapse (Bosker et al. 2017;
Ersche et al. 2012; Goldstein and Volkow 2002; Robbins et al.
2012). Although attentional bias and response disinhibition are
distinct phenomena, attentional bias can clearly be influenced by
cognitive control mechanisms including response inhibition (Bari
and Robbins 2013). In particular, inhibitory mechanisms are fun-
damental in attentional tasks for limiting the amount of informa-
tion accessible at any time and filtering out distracting environ-
mental cues that may degrade behavioural performance (Bari and
Robbins 2013).
It follows that attenuating attentional bias to cocaine-related
cues and potentiating response inhibition, via psychotherapy
and/or pharmacotherapy, might help the development of new
treatments to reduce cocaine-taking behaviour (Marhe et al.
2014). One potential approach could utilize pharmacological in-
terventions to enable CDIs to recruit greater cognitive control to
reduce attentional bias to cocaine-related cues and ameliorate re-
sponse inhibition. An excellent candidate for this approach is
atomoxetine, which inhibits the reuptake of noradrenaline in the
synaptic cleft by blocking the noradrenaline transporter
(Kratochvil et al. 2003). There is accumulating evidence that
dysfunctioning noradrenergic transmission may be important in
cocaine addiction (Schmidt and Weinshenker 2014), consistent
with data from animal research showing that atomoxetine may
attenuate the risk for relapse following cocaine abstinence
(Economidou et al. 2011). However, a clinical trial that investi-
gated the efficacy of atomoxetine in reducing cocaine use in CDIs
was less promising than initial comparative studies (Walsh et al.
2013). Nevertheless, these are not necessarily conflicting findings,
as drug taking and drug relapse have been shown to be separate
processes that may involve distinct neural circuitry and, in many
cases, can be differentially affected by pharmacotherapy. For ex-
ample, both clinical and pre-clinical studies have shown that NET
inhibitors may not be effective in decreasing ongoing drug use
whilst other adrenergic agents (e.g. alpha 2 agonists) may reduce
drug relapse (Fox and Sinha 2014; Fox et al. 2015; Smith and
Aston-Jones 2011).
Investigating how atomoxetine influences key neurocognitive
markers such as attentional bias to cocaine-related cues and re-
sponse inhibition in CDIs has therefore the potential to advance
from purely descriptive accounts of behavioural problems to pre-
dictive and mechanistic models with the prospective for novel,
rational, and individualized therapies. The main aim of this study
was to test the hypothesis that a single dose of atomoxetine,
relative to placebo, attenuates attentional bias to cocaine-related
cues and potentiates response inhibition in CDIs. We employed
two well-validated cognitive tasks that consistently index atten-
tional bias and response inhibition (Chamberlain et al. 2009;
Luijten et al. 2011; Noel et al. 2005). To elicit attentional bias
to cocaine-related cues in CDIs, we adapted a task in which
participants have to count the number of lines superimposed over
distracting cocaine-related pictures (e.g. people smoking crack)
(Luijten et al. 2011). The main advantage of this paradigm is that
cocaine-related photographs evoke stronger reactions (thereby
amplifying the attentional bias) in CDIs compared to the word
stimuli typically used in Stroop tasks (Boyer and Dickerson
2003; Cane et al. 2009; Cox et al. 2006; Ryan 2002).
Impulsivity and inhibitory control were assessed using a
go/no-go task which included cocaine-related words as the
main stimuli and control stimuli with motivational/appetitive
salience (i.e. food-related words) (Noel et al. 2005).
Atomoxetine (40 mg) has been found to potentiate response
inhibition in healthy individuals (Chamberlain et al. 2006).
Whilst some studies have failed to replicate this effect
(Nandam et al. 2011) or have found opposite results (Graf
et al. 2011), this might have depended critically on the dose
of atomoxetine; in the present study, we employed the optimal
dose (40 mg) as used previously (Chamberlain et al. 2006).
Finally, we explored whether and how clinical and person-
ality variables (i.e. years of cocaine abuse, dysphoric mood,
trait impulsivity) influenced the cognitive enhancing effects of
atomoxetine (i.e. decreased attentional bias to cocaine-related
cues and enhanced inhibitory control). Although we did not
formally assess a possible diagnosis of attention-deficit/hyper-
activity disorder (ADHD) using the DSM-IV criteria, the CDI
individuals completed the adult ADHD Self-Report Scale
(ASRS), which is a measure of individual differences in
ADHD symptoms (Kessler et al. 2005). This is because pre-
vious evidence showed that atomoxetine may be useful in
CDIs with ADHD symptoms (Levin et al. 2009).
Participants and methods
Participants
The study was approved by the National Research Ethics
Committee and all participants provided written informed
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consent. Twenty-eight individuals who met the DSM-IV-TR
criteria for cocaine dependence and 28 age- and gender-
matched healthy controls with no history of dependence or
other neuropsychiatric disorders took part in the study.
Individuals with CDI were recruited via local treatment ser-
vices and word of mouth. The healthy volunteers were recruit-
ed from the Cambridge BioResource volunteer panel (www.
cambridgebioresource.org.uk).
All participants were screened for medical and neuropsy-
chiatric disorders by medical history, laboratory testing, phys-
ical examination, and electrocardiogram. Exclusion criteria
for all participants were as follows: (1) any current or past
serious medical illness such as hepatic, cardiac, renal, infec-
tious, metabolic, or pulmonary disease; (2) any history of
traumatic head injury; (3) pregnancy; (4) no proficiency in
English; and (5) any involvement in a clinical trial investigat-
ing drug effects within the past 6 months. For controls, a
personal history of any psychiatric disorder led to exclusion
whilst for the cocaine group, a personal history of a psychotic
disorder led to exclusion.
All participants were screened for current psychiatric dis-
orders using the Mini-International Neuropsychiatric
Inventory (MINI) (Sheehan et al. 1998), and drug use was
further evaluated using the Structured Clinical Interview for
DSM-IV (SCID) (First 2002). Participants also completed the
National Adult Reading Test (NART) to assess verbal intelli-
gence quotient (IQ), the Beck Depression Inventory (BDI-II)
to record dysphoric mood, the Spielberger State-Trait Anxiety
Inventory (STAI) to evaluate anxiety levels, and the Barratt
Impulsiveness Scale (BIS-11) to assess trait impulsivity. CDIs
completed the obsessive-compulsive drug use scale (Franken
et al. 2002) and the ASRS scale to assess for individual dif-
ferences in ADHD symptoms (Kessler et al. 2005). Last, self-
reported feelings of cocaine craving in CDIs were collected
immediately after each testing session (i.e. placebo and
atomoxetine).
The attentional bias task to cocaine-related cues and go/no-
go task were conducted at the Addenbrooke’s Hospital in
Cambridge (UK) in two separate sessions following a
double-blinded design with a counterbalanced order across
participants and treatment (i.e. atomoxetine, placebo). On
each session, urine samples were analysed for cocaine. All
the urine samples provided byCDIs tested positive for cocaine
and all of the urine samples provided by the controls tested
cocaine negative. The absence of acute alcohol intoxication
was verified using breath tests. At the beginning of each ses-
sion, a single dose of 40mg atomoxetine or placebo was given
orally and vital signs were measured. Participants were dosed
either at 11.00 am or at 12.00 pm. After approximately 2 h,
vital signs were measured again and blood samples taken to
assess atomoxetine plasma concentrations. Finally, approxi-
mately 2.5 h after atomoxetine dosing, all volunteers per-
formed the cognitive tests. This schedule was based on
pharmacokinetics data declared in the Strattera® (atomoxetine
hydrochloride) leaflet which reports that plasma concentration
of atomoxetine peaks approximately 2 h after a single oral
dose of 40 mg and remains at ~60% peak up to 6 h.
Experimental tests
Line-counting task with cocaine-related and neutral pictures
We employed a modified version of the paradigm originally
developed by Luijten et al. (2011), in which participants were
asked to indicate, via a button-press response, the number of
lines superimposed on photographic images displayed on the
screen. Seventy-two coloured photographs, half depicting im-
ages of non-cocaine-related objects and activities (household
items; individual handling household items) and the other half
showing cocaine-related objects and activities (a crack pipe;
individual smoking a crack pipe), were presented twice to
participants. On each photograph, semi-randomly spaced blue
horizontal lines were superimposed. The number of lines var-
ied between 2 and 5, and participants had to respond by press-
ing the corresponding number keys on the keyboard. The
images were matched across the two conditions (neutral, co-
caine) for colour, brightness, object size, object position, and
the number of blue lines laid over them.
The task was administered in eight runs, each consisting of
a block of nine neutral images and nine cocaine-related pho-
tographs. The order of the category to be shown first within a
block (neutral or cocaine) was randomized to control for order
effects. Each photograph was displayed in the centre of the
computer screen for 900 msec and participants were asked to
respond as soon as possible when the picture appeared on the
screen. The inter-stimulus interval was jittered across trials
and on average lasted 1750msec. All participants were trained
on the task with a practice run of 30 unrelated colour photo-
graphs (depicting animals, people, or landscapes) to familiar-
ize themselves with the task and the response buttons.
Attentional bias to cocaine-related pictures was quantified
by an interference score, which was calculated as the mean
latency of correct responses to the cocaine-related images mi-
nus the mean latency to correct responses to the non-cocaine-
related images.
Go/no-go task with cocaine-related and food-related words
A modified version of a verbal go/no-go task previously de-
veloped by Noel et al. (2005) was employed. The task includ-
ed cocaine-related words and food-related words, each of
which was displayed, one by one, in the middle of the screen.
Half of the words were targets to which participants were
instructed (via a visual cue) to respond as quickly as possible
by pressing a button, and half of them were distracters to
which participants had to refrain responding. Each word was
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presented for 500 msec, with an inter-stimulus interval of
900 msec between two words.
Eighteen word stimuli (nine cocaine-related words and
nine food-related words) were grouped in a block, and within
each block, either cocaine- or food-related words were speci-
fied as targets. The cocaine- and food-related words were as
closely matched as possible in terms of word length and fre-
quency. Examples of cocaine-related words were ‘amphet-
amine’, ‘crack’, and ‘dealer’, whilst words like ‘marshmal-
lows’, ‘pizza’, and ‘cherry’ were used as food-related words.
Whether participants started with cocaine-related or food-
related words was randomized within each group. Reaction
times (RTs) to respond to a target were calculated for all par-
ticipants and RTs <100 msec (anticipated responses) were
excluded from the analyses.
As in a previous study (Sahgal 1987), we computed the num-
ber of false alarms (i.e. response to a distracter) and hits (correct
response to a target) that were both used to calculate a response
bias score. The response bias score was calculated as follows:
response bias = −0.5 × (Z (corrected probability of hits) + Z
(corrected probability of false alarms)), where Z scores were cal-
culated using the inverse phi function, which determines the Z
score of P values. The corrected probability of hits was also
computed as follows: corrected probability of hits = (number of
correct go responses +0.5)/(total number of go trials +1) and the
corrected probability of false alarms = (number of incorrect no-go
responses +0.5)/(total number of no-go trials +1).
Given that the response bias score takes into account both
correct responses and false alarms, it can be considered a
better indicator of impulsivity and disinhibition than false
alarms alone (Sahgal 1987). A more negative response bias
score reflects higher impulsivity (Noel et al. 2005).
Plasma analysis
Plasma levels of atomoxetine were analysed in all participants,
with a high-performance liquid chromatographic method
(Agilent Technologies GmbH, Waldbronn, Germany).
Separation of atomoxetine and mianserine (internal standard)
was performed on an Agilent Zorbax Eclipse XDB C8 re-
versed phase column. Detection wavelength was 218 nm,
and the limit of quantitation was 2.0 μg/l. Importantly, there
were no any additional peaks in the samples indicative of
atomoxetine metabolites.
Statistical analyses
Data were analysed using the SPSS (v.24) software.
Independent two sample t tests were used for group compar-
isons on demographic, cognitive, and personality variables as
well as vital signs (i.e. pulse, systolic, and diastolic blood
pressure).
Furthermore, the interference scores for the line-counting task
and the response bias scores for the cocaine-related go/no-go task
were entered in repeated-measure general linear models (GLM)
that tested for (1) the main effect of group, (2) main effect of
treatment, (3) main effect of stimulus (for the go/no-go task),
and (4) any group × treatment interaction or group × stimulus
and group × treatment × stimulus interaction (the latter two only
for the go/no-go task). The main effect of and interactions involv-
ing the stimulus (cocaine, food) were only possible for the drug-
related go/no-go task as the interference scores for the attentional
bias task were calculated in terms of reaction times to cocaine-
related minus neutral stimuli.
Individual plasma levels of atomoxetine were correlated
(using the Pearson’s correlation coefficient) with (1) the differ-
ence in the interference measures during the attentional bias task
(calculated by subtracting the interference scores during placebo
from the same metrics under atomoxetine) and (2) the difference
in the response bias scores during the cocaine-related go/no-go
task (computed by subtracting the response bias indices during
placebo from the same metrics under atomoxetine). Using
repeated-measure GLM, we also assessed whether self-reported
feelings of cocaine craving changed after each tasks and whether
they were influenced by atomoxetine.
Finally, the differences in the interference scores between
atomoxetine and placebo conditions for the line-counting task
as well as the differences for the response bias scores for the
cocaine-related go/no-go paradigm were correlated with the
BDI-II, BIS-11, and ASRS scores as well as with the number
of years of cocaine use. All statistical tests performed were two-
tailed and the significance level threshold was set at P < 0.05.
Results
Demographics, cognitive, and personality data
The groups were well-matched in terms of gender and age
(Table 1). Furthermore, there were no differences between
groups in pulse rate, systolic, or diastolic blood pressure sug-
gesting that cocaine users were not acutely intoxicated
(Table 1). CDIs scored significantly higher on the BDI-II
and BIS-11 questionnaires compared to controls (Table 1).
Self-reported feelings of cocaine craving did not increase sig-
nificantly after the task (F1,25 = 1.83, P = 0.18) and were not
affected by atomoxetine (F1,25 = 0.59, P = 0.44).
Behavioural performance
Attentional bias during the line-counting task
with cocaine-related and neutral pictures
There was a significant main effect of group with increased
interference scores in CDIs relative to controls, reflecting
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increased attentional bias to cocaine-related photographs in
CDIs (F26 = 5.34, P = 0.02) (Fig. 1). Whilst there was no
significant main effect of treatment (F26 = 2.42, P = 0.13),
there was a significant group × treatment interaction
(F26 = 6.73, P = 0.01). Specifically, post hoc analyses showed
that atomoxetine reduced the attentional bias to cocaine-
related pictures in CDIs but there was no difference between
atomoxetine and placebo in controls (Fig. 1).
Response inhibition during the go/no-go task with cocaine-
and food-related words
There was no main effect of group (F26 = 0.64, P = 0.42) or
treatment (F26 = 0.08, P = 0.77), although we found a main
effect of stimulus type which was driven by increased re-
sponse bias to cocaine relative to food-related words
(F26 = 6.37, P = 0.01) (Fig. 2). There was no significant group
× treatment interaction (F26 = 0.15, P = 0.69), although a
trend towards statistical significance for the group × stimulus
× treatment interaction was found (F26 = 3.38, P = 0.07). A
post hoc comparison between groups during the placebo con-
dition was not statistically different (T = 1.15, P = 0.13)
indicating that CDIs were not more impulsive than controls
on baseline.
Correlational analyses
No significant correlations were found between plasma
atomoxetine levels and (1) the difference between interference
scores under atomoxetine and the same measures under pla-
cebo for the attentional bias task and (2) the differences be-
tween response bias scores under atomoxetine and the same
measures under placebo for the cocaine-related go/no-go task
(Pearson’s r’s < 0.19, P’s > 0.18 or r’s > −0.21, P’s > 0.11).
On examining the relationship between the attentional bias
to cocaine-related cues, response inhibition measures, and
clinical as well as personality variables (i.e. years of cocaine
use, BDI-II, BIS-11, and ASRS scores), we found that the
difference in attentional bias measures between atomoxetine
and placebo conditions was only (and positively) correlated
with the years of cocaine use (Person’s r = 0.48, P = 0.02). In
other words, CDIs with the longest history of cocaine use
gained the least benefit from atomoxetine in terms of reducing
attentional bias to cocaine-related cues. However, excluding
Table 1 Demographics, cognitive, personality, and baseline characteristics of the sample
Controls (n = 28) CDIs (n = 28) Group differences
Age (years ± SD) 44.7 ± 7.4 41.1 ± 7.4 F = 0.14, P = 0.70
Gender (males/females) 26/2 27/1 NS
Education (years ± SD) 12.8 ± 2.8 11.5 ± 1.8 F = 4.7, P = 0.03
Verbal IQ, NART (mean scores ± SD) 115.2 ± 6.7 102.3 ± 8.4 F = 0.94, P = 0.33
Dysphoric mood, BDI-II (mean score ± SD) 3.0 ± 4.3 16.0 ± 8.6 F = 13.2, P = 0.001
Trait impulsivity. BIS-11 (mean score ± SD) 58.4 ± 6.8 72.9 ± 9.9 F = 5.3, P = 0.025
Trait anxiety, STAI (mean score ± SD) 29.1 ± 7.2 41.7 ± 8.4 F = 36.7, P < 0.001
Adult ADHD self-report scale (ASRS) 40.7 ± 8.3 48.4 ± 9.5 T = 3.2, P = 0.002
Pulse rate (ppm ± SD) 67.3 ± 11.8 70.6 ± 12.0 F = 0.003, P = 0.96
Systolic blood pressure (mmHg ± SD) 121.2 ± 11.5 120.9 ± 14.3 F = 1.1, P = 0.29
Diastolic blood pressure (mmHg ± SD) 73.6 ± 8.9 73.2 ± 9.8 F = 0.26, P = 0.60
Discrimination data (D′) during the go/no-go task for the drug word stimuli (on atomoxetine) 2.7 ± 0.8 1.8 ± 1.0 T = 3.4, P = 0.001
Discrimination data (D′) during the go/no-go task for the drug word stimuli (under placebo) 2.7 ± 0.8 1.8 ± 0.8 T = 3.9, P < 0.001
Discrimination data (D′) during the go/no-go task for the food word stimuli (on atomoxetine) 3.0 ± 0.7 2.2 ± 0.8 T = 3.9, P < 0.001
Discrimination data (D′) during the go/no-go task for the word stimuli (under placebo) 2.9 ± 0.7 1.9 ± 0.8 T = 4.6, P < 0.001
The discrimination data during the go/no-go task were calculated using a signal detection analysis (D′) (Snodgrass and Corwin 1988). D′ < or = 0
indicates that participants were either unable to discriminate targets from distracters or they were not performing the task as instructed. A D′ > 0 reflects
good discrimination ability (e.g. more hits and less false alarms)
SD standard deviation, CDIs cocaine-dependent individuals, IQ intelligence quotient, NART National Adult Reading Test, BDI-II Beck Depression
Inventory-second edition, BIS-11 Barratt Impulsiveness Scale-11, STAI Spielberger State-Trait Inventory, ppm pulse per minute, NS not significant by
means of a χ2 test
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an individual with 5 years of cocaine use made this result of
borderline significance (r = −.38, P = 0.08), so we no further
discuss it.
Discussion
We provide new evidence that atomoxetine significantly de-
creased attentional bias to cocaine-related stimuli in cocaine-
dependent individuals (CDIs). Overall, these findings show
that atomoxetine impacts on a key neurocognitive measure
in cocaine addiction—i.e. attentional bias to cocaine-related
cues (Marhe et al. 2013; Marissen et al. 2006).
Although the molecular mechanisms of the cognitive en-
hancing properties of atomoxetine require further investigation,
a previous animal study has demonstrated that atomoxetine
diminishes tonic firing of the locus coeruleus (LC) whilst leav-
ing phasic bursting intact (Bari and Aston-Jones 2013).
Together, these mechanisms are in keeping with the traditional
theory of LC noradrenergic function which posits that
Fig. 2 The plot displays the differences between groups, stimulus type,
and treatment conditions in the response bias score (an indicator of
impulsivity). Overall, atomoxetine reduced impulsive responding for
drug-related target words and had the opposite effect when food-related
words were the target, particularly in people with cocaine addiction
Fig. 1 This figure displays the differences between groups and treatment
conditions in the interference measure (an index of attentional bias) that
was calculated by subtracting the mean response latency during non-
drug-related conditions (bottom right panel for an example) from the
mean response latency during drug-related pictures presentation (top
right panel for an example). Overall, there was a significant main effect
of group that was driven by a generally increased attentional bias to drug-
related cues in cocaine-dependent individuals relative to controls. More
importantly, however, there was a significant group by treatment
interaction that was dependent on the fact that atomoxetine
administration reduced the attentional bias to drug-related pictures
selectively in the cocaine group. Black circles represent the mean values
per each group and treatment condition whilst the capped lines denote the
standard errors
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performance on cognitive tasks is optimal at intermediate levels
of tonic noradrenergic transmission but deteriorates when too
little or too much noradrenaline is available (Aston-Jones et al.
1999; Bari and Aston-Jones 2013). In the context of our data,
we speculate that atomoxetine may alter the balance between
the tonic and phasic LC firing which overall reduces
distractibility and attentional bias to cocaine-related cues in
CDIs (Bari and Aston-Jones 2013). Conversely, atomoxetine
did not influence task performance in controls as these persons
already display an optimal range of noradrenaline transmission,
and perhaps more importantly, as expected, they did not show
attentional bias to cocaine-related cues. Consequently, it
remains to be tested whether atomoxetine can also modulate
other types of attentional bias in healthy individuals.
In terms of likely terminal domains for the effects of
atomoxetine, the drug increases noradrenaline levels in the
prefrontal cortex (PFC) which in turn would enhance ‘top-
down’ cognitive control (Arnsten 2009). Atomoxetine has
also been found to increase extracellular levels of dopamine
as well as noradrenaline in the PFC (Bymaster et al. 2002) and
so it is also possible that the present effects were mediated by
PFC dopamine. However, a previous study reported that the
effects of atomoxetine on response inhibitory control in rats
were mediated by noradrenergic rather than dopaminergic
neurotransmission (Bari et al. 2011). A non-mutually exclu-
sive possibility is that atomoxetine simultaneously affects
noradrenergic- and dopaminergic-related mechanisms which
in turn act in concert to modulate specific PFC circuits medi-
ating attentional control (Briand et al. 2007).
In addition, we found a trend towards statistical signifi-
cance (P = 0.07) for the group × stimulus × treatment interac-
tion during the go/no-go task. A post hoc comparison between
groups during the placebo condition was not statistically dif-
ferent (T = 1.15, P = 0.13) indicating that CDIs were not more
impulsive than controls on baseline. However, this result may
warrant a replication with larger samples.
Our findings suggest new avenues for future research, for
example, to elucidate the brain mechanisms underlying the
atomoxetine effects on attentional bias to cocaine-related cues
using functional magnetic resonance imaging (fMRI). A
previous fMRI study found that smokers, relative to non-
smokers, showed greater dorsal anterior cingulate cortex
(dACC) activity whilst attending to task-relevant information
in the presence of distracting smoke-related cues (Luijten et al.
2011). This indicates that smokers excessively recruit the
dACC to achieve the necessary attentional control for task
performance. Increased dACC activation during a Stroop
paradigm has also been found to predict relapse in cocaine
use 3 months after detoxification (Marhe et al. 2013).
Together, these results suggest that task-related brain function
in specific regions could be a promising biomarker in people
with substance dependence, although it remains to be elucidat-
ed whether it can be used to identify those CDIs most likely to
benefit from pharmacological interventions such as
atomoxetine.
Although a previous clinical trial provided no support for
the use of atomoxetine in treating cocaine dependence (Walsh
et al. 2013), this null finding may have in part been due to the
lack of reliable neurocognitive indices to stratify patients and
to the use of pharmacological treatments which were limited
in time. Hence, studies assessing the effects of chronic
atomoxetine therapy to evaluate long-term changes in
neurocognitive and behavioural outcome measures in selected
groups of CDIs are warranted.
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